Upfront Diagnostics, Vingmed Group team up on rapid stroke testing in the Nordics

Upfront Diagnostics has partnered with Vingmed Group to distribute its LVOne blood test across Sweden, Denmark, Finland and Norway, aiming to speed triage for suspected large vessel occlusion strokes. The deal targets more than 100,000 stroke alerts a year and could help bring specialist-level decision-making closer to patients before hospital treatment.

Why it matters: - The partnership is designed to speed diagnosis for large vessel occlusion strokes, one of the most time-critical stroke types. - Faster triage can help move the right patients to thrombectomy sooner, which can affect outcomes in acute neurological emergencies. - The deal expands access to stroke diagnostics across the Nordic region, where emergency teams handle more than 100,000 stroke alerts each year.

What happened: - Upfront Diagnostics, a UK-based MedTech company, formed a strategic partnership with Vingmed Group, a Nordic distributor of advanced medical equipment. - Vingmed will serve as the authorised distributor for LVOne across Sweden, Denmark, Finland and Norway. - The companies announced the agreement on September 29, 2026. - The partnership is intended to extend beyond the Nordics as part of Upfront Diagnostics' broader EU distribution strategy.

The details: - LVOne is a rapid blood test designed to help identify large vessel occlusion strokes at the point of care within minutes. - The test uses biomarkers to support pre-hospital triage decisions by emergency teams. - Upfront Diagnostics says the technology can help identify patients most likely to benefit from specialist interventions. - The collaboration combines Upfront Diagnostics' diagnostic technology with Vingmed Group's distribution network and market expertise. - Vingmed's acute and emergency care diagnostics portfolio gains a new stroke-focused product. - Kolbjørn Haarr, CEO of Vingmed Group, said the partnership strengthens the company's commitment to faster clinical decision-making and improved patient care in time-critical conditions. - Gonzalo Ladreda, CEO and co-founder of Upfront Diagnostics, said the partnership is a major step toward making rapid stroke diagnosis a standard of care worldwide.

Between the lines: - The agreement reflects a push to decentralise stroke testing, moving triage earlier in the care pathway and closer to the patient. - That shift could reduce delays between first medical contact and treatment decisions, especially in systems where specialist imaging or stroke expertise is not immediately available. - The deal also gives Upfront Diagnostics a commercial route into a region with established healthcare systems and a high volume of stroke alerts.

What's next: - Vingmed is expected to begin promoting and distributing LVOne across the Nordics under the new agreement. - Upfront Diagnostics will use the partnership to support wider European and global commercialisation of LVOne. - The companies are positioning the test as part of a longer-term effort to make rapid, decentralised stroke diagnosis standard practice.